Panax Clinical Research | Miami Lakes, FL

Research site

(Unclaimed)

Location

14600 NW 60th Avenue, Unit B, Miami Lakes, Florida, United States of America

Site insights

Top conditions

Top treatments

SEL-212

Relamorelin

ESK-001

Plozasiran

Nitazoxanide

ALT-801

BI 685509

HU6

Amisulpride

Tirzepatide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 62 total trials

Locations recently updated

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) (MOVe-NOW)

Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symp...

Enrolling

Coronavirus Disease (COVID-19)

Drug: Placebo

Drug: Molnupiravir

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting

Chronic Kidney Disease

Overweight

Drug: Orforglipron

Drug: Insulin Glargine

A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function

The purpose of this study is to help determine the right dose of LY3537982 in participants with kidney problems, particularly those with severe kidne...

Enrolling

Renal Insufficiency

Drug: LY3537982

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with mod...

Enrolling

Alzheimer Disease

Drug: Placebo

Drug: KarXT

A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function

This is a phase 1, open-label, single-dose, parallel-cohort study to determine the pharmacokinetics (PK) of divarasib in healthy participants and par...

Enrolling

Hepatic Impairment

Drug: Divarasib

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

The purpose of this study is to support the development of remibrutinib dosing recommendations for patients with impaired renal function.

Enrolling

Autoimmune and Chronic Inflammatory Diseases

Drug: remibrutinib

A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

A study to investigate the pharmacokinetics of tirabrutinib in participants with mild, moderate, and severe hepatic impairment compared to healthy pa...

Enrolling

Primary Central Nervous System Lymphoma (PCNSL)

Drug: Tirabrutinib

A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight

This study is open to adults who are at least 18 years old and have* presumed or confirmed NASH together with overweight or obesity and* a body mass...

Active, not recruiting

Non-Alcoholic SteatoHepatitis (NASH)

Obesity

Drug: Survodutide

Drug: Placebo

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer pa...

Enrolling

Hepatic Impairment

Drug: ESK-001

An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer pa...

Enrolling

Renal Impairment

Drug: ESK-001

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of car...

Enrolling

Overweight

Atherosclerotic Cardiovascular Disease

Drug: Maridebart Cafraglutide

Drug: Placebo

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardi...

Enrolling

Cardiovascular Disease

Drug: Olpasiran

Drug: Placebo

Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepat...

Active, not recruiting

Fatty Liver

Nonalcoholic Steatohepatitis

Drug: HU6

Other: Placebo

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia (MUIR-3)

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). A...

Active, not recruiting

Hypertriglyceridemia

Drug: Placebo

Drug: Plozasiran Injection

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia (SHASTA-3)

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (...

Active, not recruiting

Severe Hypertriglyceridemia

Drug: Plozasiran Injection

Drug: Placebo